Liprin-β1 is upregulated in human hepatocellular carcinoma and is associated with advanced tumor stage

Xinying Li¹, Jingmei Li¹,* and Jiao Yang²,#

¹School of Life Science and Technology, Changchun University of Science and Technology, Changchun, 130022, China
²Jiangsu Key Lab of Medical Optics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, 215163, China

Corresponding authors: *ljm3023@126.com; #yangjiao@sibet.ac.cn

Received: January 16, 2019; Revised: April 3, 2019; Accepted: April 25, 2019; Published online: May 10, 2019

Abstract: Liprin-β1 is one of the broadly-expressed liprin family members. Dysregulation of liprin-β1 has been implicated in several types of human cancers. However, the expression of liprin-β1 and its clinicopathological significance in human hepatocellular carcinoma (HCC) remains elusive. We evaluated the protein expression of liprin-β1 in HCC and non-tumor liver tissues by immunohistochemistry, and investigated the relationship between liprin-β1 expression and the clinicopathological attributes of HCC. We found that liprin-β1 expression was significantly higher in HCC than in non-tumor liver tissues. Further analysis showed that higher levels of liprin-β1 in HCC were significantly associated with the advanced clinical stage. Interestingly, liprin-β1 was not detected in cholangiocellular carcinoma specimens. These findings suggest that an elevated expression of liprin-β1 may be involved in HCC progression, providing the rationale that upregulation of liprin-β1 may serve as a novel biomarker for human HCC.

Keywords: liprin-β1; hepatocellular carcinoma; cholangiocellular carcinoma; cirrhosis.

INTRODUCTION

Hepatocellular carcinoma (HCC) remains the leading cause of cancer-related mortality worldwide, with more than half a million new cases diagnosed per year [1-3]. Because of the insidious onset of the disease, HCC tends to be diagnosed at advanced stages and responds poorly to therapy [4,5]. Adverse prognosis can be attributed to the high frequency of local recurrence, intrahepatic invasion and distant metastases. Thus, identification of key factors implicated in HCC progression may be helpful in classifying tumor stages and predicting clinical outcomes.

The LAR protein-tyrosine phosphatase-interacting protein (liprin) family was originally found to be essential for the assembly of functional presynaptic active zones and postsynaptic sites in neurons [6,7]. The mammalian liprin family includes four liprin-α (liprin-α1 to -α4) proteins and two liprin-β (β1 and β2) proteins [8], which together form heterodimers and act as scaffolds [9]. A number of recent studies have revealed broader functions of the liprin family in regulating the development and homeostasis in other organs, including the mammary gland and lymphatic vessel [10,11]. Notably, analysis of human cancers has revealed dysfunctions of the liprin proteins, with evidence pointing to the different roles of liprin family members in distinct aspects of tumor biology. For example, overexpression of liprin-α1 promotes breast cancer cell invasion by regulating lamellipodia stability and integrin-mediated focal adhesions [10,12]. By contrast, liprin-β2 impairs cell motility and suppresses tumor invasion, which is indicative of its role as a tumor suppressor [10].

Liprin-β1, encoded by PPFIBP1, is one of the broadly-expressed liprin members. Emerging evidence suggests that liprin-β1 is involved in the progression of various human cancers, including breast cancer and melanoma [10,13]. Oncogenic events related to liprin-β1 include aberrant fusion, alternative splicing, local chromosome amplification and transcriptional upregulation [14-17], indicating that liprin-β1 may serve as a putative biomarker and therapeutic candidate.
in these cancer types. However, the clinical relevance of liprin-β1 in HCC has not yet been investigated.

In the present study, we assessed liprin-β1 expression in primary HCC specimens and evaluated its association with a series of histopathological parameters. In addition, the expression of liprin-β1 in cholangiocellular carcinoma (CCC), the second most common primary liver cancer, was also determined.

MATERIALS AND METHODS

Ethics statement, patient samples, and clinical information

This study was conducted on precollected samples. A total of 48 HCC specimens, 5 CCC specimens and 12 tissues from patients with cirrhosis were collected at Tongxu People’s Hospital, Henan, China. All tissues were collected under the highest ethical standards between 2005 and 2010, and approved by the Research Ethics Committee of Tongxu People’s Hospital (2005DKA21300). Consent forms were signed by all patients. The study protocol was reviewed and approved by the Research Ethics Committee of Tongxu People’s Hospital (BC03117). The clinicopathological characteristics of the patients are summarized in Supplementary Table S1, with detailed information, including patient gender, age of diagnosis, tumor grade, lymph node metastasis, and tumor-node-metastasis (TNM) stage listed in Supplementary Table S2.

Immunohistochemistry and quantification

The protein levels of liprin-β1 were determined using immunohistochemistry (IHC). Briefly, the tissue microarray samples were deparaffinized in xylene and hydrated. Antigen retrieval was performed with Tris-EDTA antigenic retrieval buffer (pH 8.0), followed by 3% H₂O₂ treatment to inhibit endogenous peroxidase activity. Tissue sections were blocked with 2% bovine serum albumin (Cat No. A8020; Solarbio, China) and incubated with anti-liprin-β1 (LS-B13770, 1:500) at 4°C overnight. The EnVision kit (DAKO) was used to detect primary antibody followed by staining with DAB reagent and counterstaining with hematoxylin. The expression of liprin-β1 was scored as 0 (absent), 1 (weak), 2 (moderate) and 3 (strong) in a double-blinded manner.

Statistical analysis

Patients were stratified into liprin-β1Low (score of 0-1) versus liprin-β1High (score of 2-3) groups. The statistical analyses were performed using GraphPad Prism software version 6.0. The association of categorical variables was examined by Fisher’s exact test and a P-value of <0.05 was considered to be statistically significant.

RESULTS

Expression of liprin-β1 was upregulated in HCC

To examine whether the expression of liprin-β1 was altered in HCC, protein levels of liprin-β1 were detected by IHC and the staining intensity of HCC samples was compared with that of non-tumor liver tissues from patients with cirrhosis (NT). The results showed that liprin-β1 was strongly stained in HCC tissues (29/48, 60%) compared with NT (2/12, 17%), where only a smaller percentage of positivity was found (Fig. 1A and B). In addition, liprin-β1 protein was confirmed to be predominantly expressed in the parenchymal cells (Fig. 1A). These expression patterns of liprin-β1 in HCC tissues suggested that liprin-β1 might be implicated in HCC formation.

Fig. 1. Expression of liprin-β1 was upregulated in HCC. A – Expression of liprin-β1 in HCC tissues and NT tissues was determined by IHC. Tumor and NT samples were stratified into liprin-β1Low and liprin-β1High groups, and representative images are shown. Scale bars, 50 μm. B – Quantification of liprin-β1 expression in NT tissues and HCC samples (P<0.001).
Liprin-β1 expression was positively correlated with TNM staging in HCC

Since the expression of liprin-β1 varied from negative to strong in human HCC samples as shown above (Fig. 1), we explored whether its levels were associated with clinicopathological features of HCC patients. Gender or age at diagnosis, the two basic parameters related to HCC development, had no impact on liprin-β1 expression (Table 1, Fig. 2A and B). Expression of liprin-β1 did not correlate with tumor differentiation status either (Table 1). Notably, a significant association between elevated liprin-β1 expression with more advanced TNM stages was evident ($P = 0.036$). HCC patients with higher liprin-β1 expression were more prone to have TNM stages III-IV (21/29, 72%) (Fig. 3A and B). Together, these data demonstrated that reduced liprin-β1 may be an indicator of malignant progression of HCC.

CCC showed lower expression of liprin-β1 than HCC

CCC represents the second most common primary liver cancer and its worldwide incidence continues to rise [18]. To test whether the expression levels of liprin-β1 protein were related to different subtypes of liver cancer, we compared the staining intensities of liprin-β1 in HCC tissues and CCC tissues. Contrary to the moderately strong staining in HCC samples (29/48, 60%) (Fig. 1), we barely detected liprin-β1 staining in CCC samples (0/5, 0%) (Fig. 4A). Comparison of liprin-β1 expression between HCC
and CCC suggested a subtype-specific upregulation of liprin-β1 in liver cancers (Fig. 4B), which needs to be confirmed by a larger population-based study.

**DISCUSSION**

Understanding the molecular genetics and pathogenesis of HCC is urgently needed to meet research and clinical demands. In the present study, we provide the first analysis of liprin-β1 protein expression in human liver cancer tissues. We reported that expression levels of liprin-β1 were enhanced in advanced HCC and was positively associated with tumor staging in HCC patients. Notably, liprin-β1 was identified as the most upregulated gene in liver tissues from patients with nonalcoholic fatty liver disease (NAFLD) compared with controls by transcriptomic profiling [19]. Considering that NAFLD can progress to nonalcoholic steatohepatitis, one of the important risk factors for HCC, the data indicate that liprin-β1 may participate in a spectrum of liver pathologies, which needs to be further ascertained. Taken together, these findings may help to improve biomarker-based HCC diagnosis and patient stratification.

Protein members of the liprin family have been implicated in several human malignancies. However, evidence supports either a pro-oncogenic role or tumor-suppressive role in different cancer types. For example, liprin-α1, encoded by PPFIA1, is amplified in breast cancer and promotes tumor invasion and metastasis [10,20,21], while in head and neck squamous cell carcinoma, liprin-α1 exhibits anti-invasive effects [22]. Together with our findings in liver cancers, these observations strongly suggest that liprin proteins, including liprin-β1, contribute to human cancers in a tissue context-dependent manner. We propose that the functional divergence of liprin-β1 may be related to different interaction partners and subcellular localization in different cell types. For example, endogenous liprin-α1 and liprin-β1 colocalize near the protruding cell front and promote cell invasion by positively regulating the organization of lamellipodia and invadopodia [12,21,23], whereas liprin-β1 shows a diffuse distribution in the cytoplasm and plays inhibitory roles in the invasive behavior of cancer cells [10,24,25].

Aside from forming dimers with other liprin members, liprin-β1 has been shown to interact with metastasis-associated protein S100A4 and phospho-binding protein 14-3-3ζ [26,27]. Consistent with the role of liprin-β1 in promoting cell motility and invasion, both S100A4 and 14-3-3ζ have been shown to facilitate epithelial-to-mesenchymal transition (EMT) and cancer metastasis in HCC [28-31], raising the possibility that these two proteins may contribute to the oncogenic role of liprin-β1 in HCC. Recent proteomics studies also demonstrated that liprin-β1 is present in several well-characterized structural complexes, including the cadherin adhesome and microtubule attachment complexes [32,33]. However, the biological functions of liprin-β1 in these signaling complexes have not been experimentally investigated. Further elucidation of the molecular mechanisms may explain the behavioral and functional variations of liprin-β1 in different cancer types.

Table 1. Relationship between clinicopathological characteristics and liprin-β1 protein expression in hepatocellular carcinoma

<table>
<thead>
<tr>
<th>Clinicopathological characteristic</th>
<th>Liprin-β1 Low (n=19)</th>
<th>Liprin-β1 High (n=29)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (median, range)</td>
<td>50.5 (35-56)</td>
<td>52 (28-67)</td>
<td>0.183</td>
</tr>
<tr>
<td>Gender [n (%)]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>female</td>
<td>3 (15.8)</td>
<td>5 (17.2)</td>
<td>0.895</td>
</tr>
<tr>
<td>male</td>
<td>16 (84.2)</td>
<td>24 (82.8)</td>
<td></td>
</tr>
<tr>
<td>T stage [n (%)]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1 &amp; T2</td>
<td>11 (57.9)</td>
<td>8 (27.6)</td>
<td>0.036</td>
</tr>
<tr>
<td>T3 &amp; T4</td>
<td>8 (42.1)</td>
<td>21 (72.4)</td>
<td></td>
</tr>
<tr>
<td>N stage [n (%)]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>15 (78.9)</td>
<td>28 (96.5)</td>
<td>0.051</td>
</tr>
<tr>
<td>N1</td>
<td>4 (21.1)</td>
<td>1 (3.5)</td>
<td></td>
</tr>
<tr>
<td>Grade [n (%)]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I &amp; II</td>
<td>10 (55.6)</td>
<td>23 (85.2)</td>
<td>0.028</td>
</tr>
<tr>
<td>III</td>
<td>8 (44.4)</td>
<td>4 (14.8)</td>
<td></td>
</tr>
<tr>
<td>/</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Clinical stage [n (%)]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I &amp; II</td>
<td>8 (42.1)</td>
<td>8 (27.6)</td>
<td>0.297</td>
</tr>
<tr>
<td>III &amp; IVA</td>
<td>11 (57.9)</td>
<td>21 (72.4)</td>
<td></td>
</tr>
</tbody>
</table>

/ = not available.
Acknowledgments: This work was supported by the Jiangsu Province Natural Science Foundation for Youths (BK20150358, BK20180222) and the China Postdoctoral Science Foundation Funded Project (2018M632375).

Author contributions: J.M.L. and J.Y. conceived and designed the experiments. X.Y.L. performed the experiments. X.Y.L. analyzed the data. J.Y. and J.M.L. contributed the reagents/materials/analysis tools. X.Y.L. wrote the manuscript. All authors read and approved the final manuscript.

Conflict of interest disclosure: None of the authors has a conflict of interest to disclose.

REFERENCES


Supplementary Data

Supplementary Table S1 and S2.
Available at: http://serbiosoc.org.rs/NewUploads/Uploads/Li%20et%20al_3876_Supplementary%20Data.pdf